News
& Events

INV-202 Induces Weight Loss and Reduces Airway Hyperreactivity in Mouse Model of Obese Asthma Montreal, Canada– May 22, 2023 – Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in […]

MONTREAL (CANADA) – April 19, 2023 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, will present at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 11:00 a.m. […]

MONTREAL (CANADA) – January 24, 2023 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities […]

Data from Phase 2 Clinical Trial May Also Provide Insights into Diabetes- and Obesity-related Complications MONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 […]